Ibogaine Treatment Shows Promising Results in 2025 Observational
Nassau, Bahamas – 2025 — Oceanside Treatment Center has released findings from a 2025 observational study examining the effectiveness of medically supervised ibogaine treatmentfor individuals struggling with fentanyl addiction. Conducted at the Center’s facility in Nassau, the study followed participants over a 12-month period to assess both short- and long-term recovery outcomes.
The observational study enrolled 48 adults diagnosed with fentanyl use disorder. All participants completed comprehensive medical screening prior to receiving ibogaine treatment in a controlled clinical setting, followed by individualized aftercare planning and ongoing recovery support.
Key Findings
The study demonstrated sustained recovery outcomes across multiple follow-up intervals:
• Three months post-treatment: 82% of participants remained abstinent from fentanyl use
• Six months post-treatment: 78% continued to maintain fentanyl-free status
• Twelve months post-treatment: 67% sustained long-term abstinence
No serious adverse events related to ibogaine administration were reported when treatment was delivered under appropriate medical supervision.
Clinical Significance
“These findings are encouraging and reflect the importance of ibogaine treatment to support both early stabilization and longer-term recovery from fentanyl dependence,” said the clinical leadership at Oceanside Treatment Center. “While addiction recovery is a complex and ongoing process, the outcomes observed in this study suggest that ibogaine—when combined with structured aftercare—may offer meaningful benefits for individuals facing severe opioid use disorders.”
Although a gradual reduction in abstinence rates over time is common in substance use disorder treatment, the majority of participants in this study maintained recovery through the 12-month follow-up period.
Study Limitations
As an observational study, the findings are not intended to establish causality. The absence of a randomized control group and the single-site design limit generalizability. Oceanside Treatment Center emphasizes the importance of continued research, including larger controlled studies, to further evaluate ibogaine’s role in addressing fentanyl addiction.
Some Closing Reflections
The 2025 observational study conducted at Oceanside Treatment Centerprovides additional evidence supporting the potential effectiveness of ibogaine treatment for fentanyl abuse when administered in a medically supervised environment. With sustained abstinence rates of 82% at three months, 78% at six months, and 67% at twelve months, the results underscore the need for ongoing clinical research as part of a broader response to the global fentanyl crisis.
About Oceanside Treatment Center
Oceanside Treatment Center is an integrative addiction recovery facility located in Nassau, Bahamas, specializing in medically supervised ibogaine treatment and comprehensive aftercare. The Center is committed to advancing evidence-informed approaches to addiction treatment while prioritizing patient safety and individualized care.
Contact Details
Oceanside Treatment Center, Bahamas
Toll Free 1-800-846-0038